%0 Journal Article
%T Adjunctive Intravitreal Bevacizumab Injection at the End of Sutureless 23 G Vitrectomy for Diabetic Vitreous Hemorrhage
%J International Journal of Ophthalmology | Ophthalmology Journals Indexed in PubMed
%D 2016
%R 10.15226/2474-9249/1/1/00113
%X This study aims to evaluate the safety and efficacy of intravitreal bevacizumab (IVB) at the end of vitrectomy in prevention of rebleeding in patients with diabetic vitreous hemorrhage. Methods: This is a retrospective interventional study comprised of 30 eyes from 30 patients who underwent 23 G pars plana vitrectomy for diabetic vitreous hemorrhage (VH). IVB (1.25 mg/0.05 ml) was injected at the end of vitrectomy. Main outcome measure was the postoperative VH and reoperation 1 and 3 months of follow-up. Other outcome measures were Best-Corrected Visual Acuity (BCVA) and Intraocular Pressure (IOP). Results: Early rebleeding within one month postoperatively occurred in 3.3%. The rate of early rebleeding was significantly reduced (p=0.002). Late VH after 1 month occurred in 6.6%. BCVA at 1 and 3 ms postoperative significantly improved (p < 0.01). There was no significant increase in the rate of reoperation (p=0.27). Conclusion: Adjunctive IVB injection at the end of vitrectomy for diabetic vitreous hemorrhage is safe and effective in reduction of early rebleeding. Keywords: Vitrectomy; Diabetic retinopathy; Bevacizuma
%U https://symbiosisonlinepublishing.com/ophthalmology/ophthalmology13.php